CAS 36507-30-9|carbamazepine-10,11-epoxide
Introduction：Basic information about CAS 36507-30-9|carbamazepine-10,11-epoxide, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | carbamazepine-10,11-epoxide | ||
|---|---|---|---|
| CAS Number | 36507-30-9 | Molecular Weight | 252.26800 |
| Density | 1.377g/cm3 | Boiling Point | 390.2ºC at 760mmHg |
| Molecular Formula | C15H12N2O2 | Melting Point | 204-206ºC |
| MSDS | ChineseUSA | Flash Point | 189.8ºC |
| Symbol | GHS09 | Signal Word | Danger |
Names
| Name | carbamazepine-10,11-epoxide |
|---|---|
| Synonym | More Synonyms |
carbamazepine-10,11-epoxide BiologicalActivity
| Description | Carbamazepine 10,11-epoxide is an orally active metabolite of Carbamazepine (HY-B0246). Carbamazepine has anticonvulsant effect. Carbamazepine can be used for the research of seizures[1]. |
|---|---|
| Related Catalog | Research Areas >>Neurological Disease |
Chemical & Physical Properties
| Density | 1.377g/cm3 |
|---|---|
| Boiling Point | 390.2ºC at 760mmHg |
| Melting Point | 204-206ºC |
| Molecular Formula | C15H12N2O2 |
| Molecular Weight | 252.26800 |
| Flash Point | 189.8ºC |
| Exact Mass | 252.09000 |
| PSA | 58.86000 |
| LogP | 3.79470 |
| Index of Refraction | 1.686 |
| InChIKey | ZRWWEEVEIOGMMT-UHFFFAOYSA-N |
| SMILES | NC(=O)N1c2ccccc2C2OC2c2ccccc21 |
| Storage condition | −20°C |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 420 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- TAKHAA Takeda Kenkyusho Ho. Journal of the Takeda Research Laboratories. (Takeda Yakuhin Kogyo K.K., 2-17-85 Jusohon-machi, Yodogawa-ku, Osaka 532, Japan) V.29- 1970- Volume(issue)/page/year: 37,12,1978 ** REPRODUCTIVE DATA **
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 9600 mg/kg
- SEX/DURATION :
- female 2 week(s) pre-mating female 1-18 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - musculoskeletal system
- REFERENCE :
- JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 279,1237,1996
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 19200 mg/kg
- SEX/DURATION :
- female 2 week(s) pre-mating female 1-18 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - other developmental abnormalities
- REFERENCE :
- JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 279,1237,1996
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- DOSE :
- 32 gm/kg
- SEX/DURATION :
- female 2 week(s) pre-mating female 1-18 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Maternal Effects - other effects Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
- REFERENCE :
- JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 279,1237,1996
Safety Information
| Symbol | GHS09 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H411 |
| Precautionary Statements | P273 |
| Hazard Codes | Xn: Harmful; |
| Risk Phrases | R22;R36/37/38 |
| Safety Phrases | 26-36 |
| RIDADR | UN 2811 |
| WGK Germany | 3 |
| RTECS | HQ4430000 |
| Packaging Group | III |
| Hazard Class | 6.1(b) |
| HS Code | 2933990090 |
Customs
| HS Code | 2933990090 |
|---|---|
| Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
Articles30
More Articles| Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy subjects. Clin. Ther. 36(11) , 1638-49, (2014) Vilazodone is a serotonin reuptake inhibitor and 5-HT1A partial agonist approved for the treatment of major depressive disorder in adults. Vilazodone seems to be metabolized primarily by the cytochrom... | |
| Evaluation of the potential for pharmacokinetic drug-drug interaction between armodafinil and carbamazepine in healthy adults. Clin. Ther. 37(2) , 325-37, (2015) Polypharmacy is common in psychiatry practice and can lead to an increased risk of drug interactions. Armodafinil, a wakefulness-promoting agent, has been studied as adjunctive therapy for the treatme... | |
| Successful treatment of carbamazepine poisoning with hemodialysis: a case report and review of the literature. Hemodial. Int. 15(3) , 407-11, (2011) A 48-year-old man was brought to the emergency room after ingesting an unknown amount of carbamazepine. He was unconscious and not responding to the noxious stimuli. He was intubated and was placed on... |
Synonyms
| 1a,10b-Dihydro-6H-dibenzo(b,f)oxireno[d]azepine-6-carboxamide |
| Carbamazepine 10,11-Epoxide |
| Carbamazepine epoxide |
| Carbamazepine-10,11-epoxide |
| Carbamazepine10,11-Epoxide |
| 6H-Dibenz[b,f]oxireno[d]azepine-6-carboxamide,1a,10b-dihydro- |
